Cover Story
SWOG earlier this week started to accrue patients to Lung-MAP, a clinical trial for second-line treatment of non-small cell lung cancer.
By Tessa Vellek
In Brief
Trending Stories
- As fire encroached, City of Hope prepared to evacuate its Duarte campus
- Pediatric cancer research cut from spending legislation at last minute
Republicans quietly removed hard-won pediatric cancer bills - After 25 years as FDA’s chief cancer strategist, Richard Pazdur reflects on opportunities for change at the agency
- New colorectal cancer screening strategies must advance the standard of care
- Weeks before death from sarcoma, Norm Coleman reflected on his career in radiation oncology and addressing health disparities
- Fran Visco awarded the Presidential Citizens Medal: “We are not going to change what we do or how we do it.”